VERA biotech catalysts & pipeline

VERA THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

atacicept — Initial data

Q4 2026

In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or anti-nephrin autoantibodies.

Source filing

atacicept — NDA/BLA submission

Q4 2026

Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in Q4 2026.

Source filing

atacicept — Full data

Q1 2027

• Pivotal two-year eGFR data from the ORIGIN 3 trial expected Q1 2027

Source filing

atacicept — Regulatory decision

2027

We look forward to the potential full approval of TRUTAKNA in 2027

Source filing

Explore the free biotech catalyst calendar